Table 1 Patients characteristics

From: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

 

FOLFIRI ( n =146)

FOLFOXIRI ( n =137)

Characteristics

n

%

n

%

Age

 Median (range)

66 (39–84)

66 (25–82)

 ⩾65 years

82

56

75

55

Sex

 Male

82

58

76

55

 Female

61

42

61

45

Performance status (ECOG)

 0

55

38

49

36

 1

74

51

73

53

 2

17

11

15

11

Localisation

 Colon

110

75

100

73

 Rectum

36

25

37

27

Sites of disease

 Liver

102

70

99

72

 Lung

46

32

42

31

 Other

63

43

61

46

Number of metastatic sites

 1

59

40

55

40

 2

63

43

57

42

 ⩾3

24

16

25

18

 Median (range)

2 (1–4)

2 (1–6)

Metastases

 Synchronous

63

43

66

48

 Metachronous

83

57

70

52

Kohne prognostic index

 Low risk

54

37

44

32

 Intermediate risk

57

39

56

41

 High risk

35

24

37

27

Prior therapy

 Adjuvant chemotherapy

48

33

49

36

 Adjuvant

 

18

 

17

 Chemoradiotherapy

 

12

 

12

Back to article page